Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmedeo Resources Regulatory News (AMED)

  • There is currently no data for AMED

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

20 Jul 2005 17:22

Creon Corporation PLC20 July 2005 For immediate release 20 July 2005 Creon Corporation plc ("Creon") Financing Completed Creon, the AIM traded provider of mezzanine finance to the UK residentialproperty development sector, is delighted to announce the successful completionof a further financing. In line with Creon's stated strategy, it has provided£390,000 to support a £2.2 million project. The development is of 5 new housesin South West England. Creon will receive an agreed finance fee on repayment ofits facility in twelve months time. Creon's Director, Jonathan Freeman comments: "Creon is successfully building itsprofile and is receiving a variety of good quality financing proposals whichmeet our strategic requirements." Roger Holbeche and Jonathan Lavy of Creon Equity LLP, consultants to Creon,comment: "The financing package offered by Creon is proving to be veryattractive to the targeted sector of the residential development market. We areworking on a number of other projects and consequently expect further financingsto be completed in the near future." Company Profile: Creon's stated strategy is to provide mezzanine finance to small and mediumsized UK residential property developers. The business is underpinned by theexperience of the Directors and of its consultants, Creon Equity LLP, who havewide-ranging experience in this market. Creon supports property developers withdemonstrable track records for developments of between £1 million and £5 millionwith funding in amounts between £250,000 and £750,000 for periods of 12 to 18months per development. For more information please contact Jonathan Freeman, Investor Relations, on01600 7500 432, e-mail: jdfreeman@creoncorporation.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Jan 20054:10 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.